Amplia Therapeutics – Corporate Presentation – June 2024

Presentation Highlights:

Amplia Therapeutics Limited (ASX: ATX) is pleased to release its latest Corporate Presentation.

• CEO and Managing Director Dr. Chris Burns will be presenting an introduction webinar of the Company in a hosted by Sharewise on June 11, 2024, at 3PM AEST, followed by a live Q&A session.
• The Company, headquartered in Melbourne, Australia, has a current market capitalization of AUD 19.6M, with notable institutional investors including Platinum, Blueflag, Acorn Capital, and Pengana Capital.
• Amplia Therapeutics is conducting a clinical trial in advanced pancreatic cancer with an interim readout planned for Q3 2024. Amplia’s Orphan Drug Designation for pancreatic cancer and idiopathic pulmonary fibrosis (IPF) have been well received for its compelling preclinical data in models of pancreatic cancer, ovarian cancer, and IPF.